Zura Bio Limited
NASDAQ:ZURABiotechnology
+$0.07 today
- Market cap
- $92.96M
- Beta
- 0.03
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.67
Volume 3.02M
Average 0.75M
ZURA Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Zura Bio LimitedNASDAQ: ZURA
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets rises 32.5% from a year ago
Total assets stood at $228.64M at the end of Q1 FY2026, up 32.5% from a year earlier and up 100.7% from the prior quarter. Over 3 fiscal years it compounded at +178.7% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total assets keeps rising in the next quarterly balance sheet after a +32.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 113.95M USD
- Year-over-year change
- -36.5%
- 4-year CAGR
- -5.1%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 113.95M | -36.5% |
| FY2024 | 2024-12-31 | 179.53M | +78.0% |
| FY2023 | 2023-12-31 | 100.84M | +1816.4% |
| FY2022 | 2022-12-31 | 5.26M | -96.3% |
| FY2021 | 2022-03-31 | 140.55M | — |
Total Assets vs competitors
How ZURA compares with its peers on the latest reported figures
- ZURA's Mar 2026 total assets of $228.64M is the 5th highest of the 11 companies compared; the peer median is $199.97M.
- Its year-over-year change of +32.5% is the 3rd highest of 11, against a peer median of -18.0%.
- Over three fiscal years its annual growth of +178.7% compares with a peer median of -12.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $214.81B | +423744.3% | +23.8% | |
| Mar 2026 | $314.7M | -2.6% | -9.6% | |
| Mar 2026 | $245.41M | -26.0% | -15.6% | |
| Mar 2026 | $235.51M | +137.8% | +36.3% | |
ZURAZura Bio Limited | Mar 2026 | $228.64M | +32.5% | +178.7% |
| Mar 2026 | $222.17M | -14.1% | -21.2% | |
| Mar 2026 | $177.78M | -21.9% | -18.3% | |
| Mar 2026 | $135.07M | -6.2% | -19.2% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $107.76M | -26.3% | +52.2% |
| Mar 2026 | $98.59M | -37.2% | +91.2% | |
| Mar 2026 | $64.3M | -52.7% | -24.3% | |
| Peer median (excluding ZURA) | $199.97M | -18.0% | -12.6% | |
Competitors are the stored peer set for ZURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Zura Bio Limited
NASDAQ:ZURA
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.